摘要:
Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1′, R2, R2′, R3, R4, R4′, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1′, R2, R2′, R3, R4, R4′, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
摘要:
Novel compounds of the formula I, in which X, Y, R, R′, R1, R1′, R1″, R2, R2′, R2″, R3, R3′, R4, R4′ and n have the meanings indicated in Patent Claim 1, are suitable as antidiabetics
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
摘要:
Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type.
摘要:
Novel 3-aminoindazoles of the formula (I) are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibrosis and inflammatory processes of any type.
摘要:
Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.